Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company
committed to delivering a new class of differentiated one-time
curative genetic therapies, today announced that the Company will
showcase advances in preclinical data across the Prime Editing
pipeline and platform at several healthcare industry conferences in
October and November 2023.
“We are pleased to share new preclinical research across our
programs, including proof-of-concept data from in vivo rodent and
large animal studies, which showcase the strength of our science,”
said Keith Gottesdiener, M.D., President and Chief Executive
Officer of Prime Medicine. “Together, we believe the breadth of
these data represents significant progress across our portfolio and
reinforces the potential of Prime Editing to offer curative genetic
therapies for a wide spectrum of diseases.”
Presentation information is as follows:
AIChE International Conference on CRISPR
Technologies
- Presentation Date: October 19, 2023
- Title: Developing and Optimizing Prime Editors
to Treat Repeat Expansion Diseases
- Location: Boston
Advances in Prime Editing technology and updates from several
Prime Medicine Repeat Expansion Disease programs.
Stem Cell Clonality and Genome Stability Retreat at
ESGCT
- Presentation Date: October 23, 2023
- Title: Prime Editing in Hematopoietic Diseases
and Beyond: Efficacy and Safety
- Location: Brussels
Overview of Prime Medicine’s comprehensive proprietary approach
to off-target analysis, including details of off-target analyses
from Prime Medicine’s programs.
Oligonucleotide Therapeutics Society (OTS) Annual
Meeting
- Presentation Date: October 24, 2023
- Title: Recent Advances in Non-Viral Delivery
of Prime Editors Toward the Treatment of Patients with Glycogen
Storage Disease Type 1b (GSD1b)
- Location: Barcelona
Advances in Prime Medicine’s lipid nanoparticle (LNP) and
all-RNA delivery platforms for liver disease.
International Symposium on Retinal Degeneration
(RD2023)
- Presentation Date: October 24, 2023
- Title: Prime Editors Efficiently and Precisely
Correct Pathological Mutations Causing Rhodopsin Associated
Autosomal Dominant Retinitis Pigmentosa (adRP)
- Location: Costa del Sol, Spain
First in vivo proof-of-concept data in adRP, including
mutational hotspot Prime Editing, initial safety data for lead
Retinitis Pigmentosa program, and highlights from Prime Medicine’s
modular retinal delivery platform.
European Society of Gene and Cell Therapy
(ESGCT)
- Presentation Date: October 27, 2023
- Title: Prime Editing Precisely Corrects
Prevalent Pathogenic Mutations Observed in Glycogen Storage Disease
Type 1b (GSD1b) Patients
- Location: Brussels, Belgium
Prime Medicine’s liver-targeted LNP and all-RNA delivery
platforms, in vivo proof-of-concept data, and first non-human
primate data for Prime Editing in GSD1b.
North American Cystic Fibrosis Conference
(NACFC)
- Presentation Date: November 4, 2023
- Title: Prime Editing to Correct Genetic
Hotspots and Prevalent Mutations Causing Cystic Fibrosis
- Location: Phoenix
Hotspot approach to developing Prime Editors to correct the CFTR
gene in a majority of patients with Cystic Fibrosis, including
those with high unmet needs; initial proof of concept results, and
Prime Medicine’s LNP and all-RNA delivery approaches for the
lung.
CRISPR 2.0
- Presentation Dates: November 29, 2023, and
November 30, 2023
- Titles:1) Recent Advancements
in Developing & Applying Prime Editors (November 29, 2023)Novel
Prime Editor proteins and highlights of additional Repeat Expansion
Disease programs.2) Precise Whole-Gene Insertion
Using PASSIGE Technology (November 30, 2023)Key updates to PASSIGE
technology, multiplex editing, and the possibility of using PASSIGE
to develop a next-generation allogeneic CAR-T cell therapy
product.
- Location: Boston
AASLD The Liver Meeting
- Presentation Date: TBD
- Title: Prime editing precisely corrects
prevalent mutations observed in Glycogen Storage Disease Type 1b
(GSD1b) patients
- Location: Boston
Additional data from Prime Medicine’s liver-targeted LNP and
all-RNA delivery platforms; in vivo proof-of-concept data in GSD1b
program; and expanded non-human primate results for Prime Editing
in GSD1b.
About Prime Medicine
Prime Medicine is a leading biotechnology company dedicated to
creating and delivering the next generation of gene editing
therapies to patients. The Company is leveraging its proprietary
Prime Editing platform, a versatile, precise and efficient gene
editing technology, to develop a new class of differentiated,
one-time, potentially curative genetic therapies. Designed to make
only the right edit at the right position within a gene while
minimizing unwanted DNA modifications, Prime Editors have the
potential to repair almost all types of genetic mutations and work
in many different tissues, organs and cell types.
Prime Medicine is currently progressing a diversified portfolio
of eighteen programs initially focused on genetic diseases with a
fast, direct path to treating patients or with a high unmet need
because they cannot be treated using other gene-editing approaches.
Over time, the Company intends to maximize Prime Editing’s
therapeutic potential and advance potentially curative therapeutic
options to patients for a broad spectrum of diseases. For more
information, please visit www.primemedicine.com.
© 2023 Prime Medicine, Inc. All rights reserved.
PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are
trademarks of Prime Medicine, Inc. All other trademarks referred to
herein are the property of their respective owners.
Cautionary Note Regarding Forward Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, implied and
express statements about Prime Medicine’s beliefs and expectations
regarding: the potential of Prime Editing to offer curative genetic
therapies for a wide spectrum of diseases. The words “anticipate,”
“believe,” “contemplate,” “continue,” “could,” “estimate,”
“expect,” “goal,” “hope,” “intend,” “may,” “might,” “plan,”
“possible,” “potential,” “predict,” “project,” “seek,” “should,”
“strategy,” “target,” “will,” “would,” or the negative of these
words or other similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words.
Any forward-looking statements in this press release are based
on management’s current expectations and beliefs and are subject to
a number of risks, uncertainties and important factors that may
cause actual events or results to differ materially from those
expressed or implied by any forward-looking statements contained in
this press release, including, without limitation, risks associated
with: uncertainties related to the authorization, initiation, and
conduct of preclinical and other development requirements for
potential product candidates, including uncertainties related to
regulatory approvals; risks related to the development and
optimization of new technologies, the results of preclinical
studies, or clinical studies not being predictive of future results
in connection with future studies; the scope of protection Prime
Medicine is able to establish and maintain for intellectual
property rights covering its Prime Editing technology; Prime
Medicine’s ability to identify and enter into future license
agreements and collaborations; and general economic, industry and
market conditions, including rising interest rates, inflation, and
adverse developments affecting the financial services industry. The
risks and uncertainties are described in greater detail in the
section entitled “Risk Factors” in Prime Medicine’s most recent
Annual Report on Form 10-K, as well as any subsequent filings with
the Securities and Exchange Commission. In addition, any
forward-looking statements represent Prime Medicine’s views only as
of today and should not be relied upon as representing its views as
of any subsequent date. Prime Medicine explicitly disclaims any
obligation to update any forward-looking statements subject to any
obligations under applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
Investor ContactHannah DeresiewiczStern
Investor Relations,
Inc.212-362-1200hannah.deresiewicz@sternir.com
Media ContactDan Budwick,
1ABdan@1ABmedia.com
Prime Medicine (NASDAQ:PRME)
Historical Stock Chart
From Apr 2024 to May 2024
Prime Medicine (NASDAQ:PRME)
Historical Stock Chart
From May 2023 to May 2024